REOLYSIN®
Sponsors
Oncolytics Biotech
Conditions
Carcinoma, Non-small Cell LungCarcinoma, Squamous Cell of the Head and NeckEwing Sarcoma Family TumorsFibrosarcomaKRAS Mutant Metastatic Colorectal CancerLeiomyosarcomaMalignant Fibrous HistiocytomaMalignant Glioma
Phase 1
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
CompletedNCT00528684
Start: 2006-07-31End: 2010-06-30Updated: 2014-10-02
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
CompletedNCT01274624
Start: 2010-12-31End: 2018-11-30Updated: 2018-12-19
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
CompletedNCT02620423
Start: 2015-12-31End: 2018-08-31Updated: 2018-09-13
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
WithdrawnNCT02723838
Start: 2017-02-28End: 2018-02-28Updated: 2017-03-07
Phase 2
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
CompletedNCT00503295
Start: 2007-06-30End: 2011-04-30Updated: 2014-10-02
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
CompletedNCT00753038
Start: 2008-08-31End: 2013-05-31Updated: 2014-11-04
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
CompletedNCT00861627
Start: 2009-03-31End: 2015-11-30Updated: 2015-12-02